TRANBERG Thermal Therapy System developer Clinical Laserthermia Systems AB (publ) (STO:CLS-B) announced on Thursday that it has received additional orders from ClearPoint Neuro, Inc (Nasdaq:CLPT), a medical device company, valued at approximately SEK7.5m.
These orders are for ClearPoint Prism products as part of ClearPoint Neuro's North American market launch initiated in early June this year. This follows previous orders totaling approximately SEK10.5m received around the turn of the year 2023/2024.
CLS and ClearPoint Neuro aim to develop and commercialize a next-generation, fully integrated laser therapy system for high-precision MRI-guided stereotactic laser ablation in neurosurgery. The integrated product solution offers streamlined workflows for identifying, navigating and positioning sterile laser applicators in target tissues, with MRI-guided monitoring and control of temperature and ablation progress.
Recent strategic steps include obtaining US-FDA 510(k) clearance for ClearPoint Neuro's Prism Bone Anchor Accessory, further strengthening the product offering and expanding the market in the US.
(EUR1=SEK11.19)
Novavax COVID-19 vaccine approved in US
Cantargia secures US patent for nadunolimab combination therapies
European Commission approves Bio-Thera Solutions' BAT2206
INOVIO to begin rolling submission of BLA for INO-3107
Cereno Scientific receives FDA Fast Track designation for CS1 in pulmonary arterial hypertension
European Commission approves Gilead's twice-yearly HIV prevention injection Yeytuo
Orsini named by Ionis as exclusive specialty pharmacy partner for DAWNZERA (donidalorsen)
Curasight's uTREAT clinical trial application approved in Europe
Coya Therapeutics wins FDA clearance to advance COYA 302 into Phase 2 ALS trial
QT Imaging signs exclusive USD33m distribution deal with Gulf Medical in Saudi Arabia
Innovent Biologics receives approval over squamous cell lung cancer study
Crinetics Pharmaceuticals' atumelnant granted US FDA Orphan Drug Designation
Advanz Pharma and Alvotech secure European approval for aflibercept biosimilar Mynzepli
Hamlet BioPharma completes Phase II study of Alpha1H in non-muscle invasive bladder cancer